Biondvax begins Phase IIa universal flu vaccine trial

The results of the clinical trial should be published by the end of the second quarter in 2011.

BiondVax Pharmaceuticals Ltd. (TASE:BNDX) today announced that it is beginning a Phase IIa clinical trial for its Multimeric-001 universal flu vaccine. The company is giving trial participants initial shots of the vaccine.

The vaccine developer announced that the trial results should be published by the end of the second quarter of 2011.

The new trial will test the safety of the vaccine and the immune response of the body to the injections and the ability of the vaccine to strengthen the immune reaction to the commercial flu vaccine, and the effect of receiving two vaccinations at the same time.

The company has so far successfully completed two Phase I/II clinical trials with the Multimeric-001 vaccine, which was found safe for use in all dosages by a statistically significant margin compared with the control group.

BiondVax president and CEO Dr. Ron Babecoff said, "Beginning this trial is a significant milestone in the clinical development of the Multimeric-001 universal flu vaccine, which is considered the first of its kind in the world. After the success of the two previous trials, in which the Multimeric-001 vaccination proved its safety and arousal of a reaction in older and younger people, the new trial is an important stage in developing the universal flu vaccine. This important trial will take us a significant step forward in realizing the company's vision of ensuring protection against flu through a single vaccination that will replace the need to be vaccinated each year as existing vaccines require today."

In early afternoon trading on the TASE, Biondvax's share price was up 2.88% to NIS 2.50.

Published by Globes, Israel business news - www.globes-online.com - on October 11, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018